After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.
Search results for: cancer
Preventive Strategies & Novel Treatments for RA
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
Medicare Drug Price Negotiation: What ACR Members Need to Know Ahead of Round Three
As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.
Key Research in Vasculitis Encapsulated
Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
Finding the Panacea: The Management of Psoriatic Arthritis
In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting
An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.
Biosimilar Update: 2025 Brings More FDA Approvals & Interchangeability
Here is a brief recap of the latest FDA-approved biosimilar agents, highlighting their reference products and interchangeability.
B Cell-Depleting Therapy in SLE & Lupus Nephritis
“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 85
- Next Page »